148 Treating newly diagnosed relapsing-remitting multiple sclerosis (RRMS): a 2021 clinician survey in the United Kingdom

Abstract

BackgroundAs new treatment approaches become available for RRMS it is important to understand clinical treatment decision-making.MethodsWe used a structured questionnaire to interview UK healthcare professionals (HCPs) about their clinical treatment approaches for RRMS.ResultsOf 38 HCPs interviewed, 53% were multiple sclerosis (MS) Consultants, 34% MS specialist nurses, 11% neurologists with an MS interest (3% other). The most important treatment goals for newly diagnosed RRMS were modifying/reducing relapse, delaying progression to disability and maintaining quality of life, reported by 63% (24/38), 58% (22/38) and 50% (19/38) of respondents, respectively. 74% of respond- ents strongly agreed and 24% agreed early treatment is essential for better outcomes in most patients. The (mean [SD]; n=37) estimated percentage of patients treated with high efficacy early or escalation approaches were 42.1% (21.8) and 58.3% (20.8), respectively; 66% of respondents agreed these proportions reflected the treatment approach they would like to take. For those disagreeing (34%), the mean (SD) reported percentage of patients they would ideally treat with high efficacy and escalation approaches were 66.2% (18.0) and 33.8% (18.0), respectively.ConclusionsWhilst the majority of HCPs agreed that early treatment of RRMS is essential, there was vari- ability in reported and ideal treatment approaches.